{"product_id":"olr1-antibody-lox-1-bha17110701","title":"Olr1 Antibody \/ Lox-1","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eOlr1 Antibody \/ Lox-1 is a research-use primary antibody intended for detection of \u003cstrong\u003eOLR1\u003c\/strong\u003e in experimental workflows. It is supplied in \u003cstrong\u003eAntigen affinity purified\u003c\/strong\u003e format. Key antibody attributes include Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG. Applications listed for this product include WB, IHC-P, FACS, Direct ELISA. Species reactivity (as provided): Mouse, Rat.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e OLR1 — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified — format can influence background, multiplexing compatibility, and downstream detection strategies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody identity:\u003c\/strong\u003e Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct notes (from provided description):\u003c\/strong\u003e OLR1 (oxidized low density lipoprotein (lectin-like) receptor 1) also called CLEC8A, LOX-1, SCARE1, is a receptor protein which belongs to the C-type lectin superfamily. The OLR1 gene encodes a cell-surface endocytosis receptor for oxidized low density lipoprotein (OxLDL). This gene is mapped on 12p13.2. Incubation of the cells with LDL had no effect on LOX1 expression, but incubation with OxLDL resulted in a dose-dependent increase in LOX1 mRNA and protein expression; however, very high concentrations of OxLDL caused a decrease in OxLDL expression, perhaps indicating toxic effects on endothelial cells. LOX1 was also expressed in macrophages, but not in vascular smooth muscle cells. The findings suggested a role for LOX1 in the pathophysiology of atherosclerotic cardiovascular disease. LOX1 expression was detected in all choroidal neovascular membranes, regardless of structure, whereas there was no evidence of LOX1 within the posterior segments of normal eyes. LOX1 plays an active role in the pathogenesis of choroidal neovascularization, especially in ARMD.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWhere multiple assay formats are possible, align the antibody format, host\/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eIn this catalog, OLR1 is positioned within \u003cstrong\u003eMolecular \u0026amp; Cellular Biology, Cardiomyopathy\u003c\/strong\u003e research contexts. For authoritative gene\/protein nomenclature, domains\/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003eHigher-plex and spatially resolved readouts (e.g., multiplex IF\/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host\/isotype and labeling strategies.\u003c\/li\u003e\n\u003cli\u003eGenetic perturbation controls (knockout\/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.\u003c\/li\u003e\n\u003cli\u003eReproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.\u003c\/li\u003e\n\u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eWB:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIHC-P:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFACS:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDirect ELISA:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTypical workflow themes:\u003c\/strong\u003e Western blot validation, IHC on FFPE tissue, Flow cytometry staining, ELISA binding assay, Specificity controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorkflow notes:\u003c\/strong\u003e Validate LOX-1 by Western blot in cell\/tissue lysates (include controls), Detect LOX-1 by IHC in FFPE tissue sections (optimize antigen retrieval + dilution), Quantify LOX-1-positive cells by flow cytometry in single-…\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWhen comparing conditions, consistent sample processing and appropriate negative\/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003eIsoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.\u003c\/li\u003e\n\u003cli\u003eSpecies and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.\u003c\/li\u003e\n\u003cli\u003eControl concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic\/orthogonal controls (e.g., KO\/KD, independent antibodies, or RNA measurements) when feasible.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eMonoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.\u003c\/p\u003e \u003c!-- Sources (internal): - UniProt Knowledgebase (UniProtKB) — UniProt Consortium — https:\/\/www.uniprot.org\/ - NCBI Gene — National Center for Biotechnology Information (NCBI) — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - Ensembl Genome Browser — EMBL-EBI — https:\/\/www.ensembl.org\/ - The Human Protein Atlas — Human Protein Atlas — https:\/\/www.proteinatlas.org\/ - Antibody validation concepts and controls (general guidance) — NIH \/ community resources — https:\/\/www.nih.gov\/ - MIQE\/experimental reporting \u0026 reproducibility (general) — Scientific community guidelines — https:\/\/www.equator-network.org\/ --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53044867694957,"sku":"RQ6064","price":449.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_236ce4e2-3671-467b-a4ea-b4d7d501bb4a.jpg?v=1782236596","url":"https:\/\/www.ebiohippo.com\/products\/olr1-antibody-lox-1-bha17110701","provider":"BioHippo","version":"1.0","type":"link"}